Tpl-2/Cot and COX-2 in breast cancer

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008 Jun;152(1):21-5. doi: 10.5507/bp.2008.003.

Abstract

Background: Breast cancer is the most common cancer in women worldwide and although mortality (129,000/year) stagnates, incidence (370,000/year) is increasing. In addition to histological type, grade, stage, hormonal and c-erbB2 status there is therefore a strong need for new and reliable prognostic and predictive factors.

Methods and results: This minireview focuses on two potential prognostic and predictive candidates Tpl2/Cot and COX-2 and summarise information about them.

Conclusion: Tumor progression locus 2 (Tpl2/Cot) is a serine/threonine protein kinase belonging to the family of MAP3 kinases. Activated Tpl2/Cot leads to induction of ERK1/2, JNK, NF-kappaB and p38MAPK pathways. The first study on Tpl2/Cot mRNA in breast cancer showed its increase in 40 % of cases of breast cancer but no available data exist on protein expression. Cyclo-oxygenase 2 (COX-2) is inducible by growth and inflammatory factors and contributes to the development of various tumours. Expression of COX-2 in breast cancer varied from 5-100 % in reviewed papers with significantly higher values in poorly differentiated tumours. Tpl2/Cot and COX-2 have their importance in different intracellular pathways and some of these are involved in cancer development. Briefly, the results from recent studies suggest that Tpl2/Cot and COX-2 could be prognostic factors in breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / physiopathology*
  • Cyclooxygenase 2 / physiology*
  • Female
  • Humans
  • MAP Kinase Kinase Kinases / physiology*
  • Proto-Oncogene Proteins / physiology*

Substances

  • Proto-Oncogene Proteins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • MAP Kinase Kinase Kinases
  • MAP3K8 protein, human